Skip to content
WithdrawnPhase 3

Endogenous Opioid Modulation by Ketamine

NCT03051945 · University of Utah

Closed to entry
Status
Not accepting participants
Phase 3
Phase
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

Demonstrate the acute effects of ketamine on endogenous µ-opioid neurotransmission in humans.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Hamilton Depression Rating Scale at 24 hours, change from baseline

    Measured over 24 hr

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 65 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Age 18-65 * DSM-5 major depressive disorder * Current moderate-to-severe, treatment-resistant, depressive episode * Patient Health Questionnaire (PHQ-9) total score ≥ 10 * PHQ-9 item score ≥ 2 on "Little interest or pleasure" item * PHQ-9 item score ≥ 2 on "Feeling down, depressed, or hopeless" item * Medical documentation of depression for at least 2 months * Inadequate response to at least one adequate antidepressant medication trial in the current episode Exclusion Criteria: * Current episode duration \>5 years * Moderate-to-severe DSM-5 substance use disorder (past year) * Cognitive disorder (past year) * Post-traumatic stress disorder (past year) * Obsessive compulsive disorder (past year) * Personality disorder (past year) * Positive urine drug screen * Psychotic symptoms * Mania * Significant neurologic disorder or injury * Breastfeeding or pregnancy * Imminent suicide risk * Current use of CYP3A4 inhibitors (e.g., ketoconazole or erythromycin) * Other unstable psychiatric or medical condition requiring a higher level of care * Contraindication to ketamine, MRI, or PET

Where

1 study site

FacilityCityRegionCountry
Huntsman Cancer InstituteSalt Lake CityUtahUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT03051945 on ClinicalTrials.gov →

Last updated in the registry 2020-01-28. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits